D&D Pharmatech
Financials
Valuation Metrics
D&D Pharmatech's Market Cap is ₩1.9T. At end of 2025 it was ₩4.2T. Ranked #202 of 2,405 in KR market (top 8%), #38 of 1,627 on KOSDAQ (top 2%), #18 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 8%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 1.90T KRW | KR#202/2,405 Sec#18/231 |
| Revenue | 2.75B KRW | KR#2,359/2,405 Sec#209/231 |
| Net Income | -21.75B KRW | KR—/2,405 Sec—/231 |
| Total Assets | 97.54B KRW | KR#1,803/2,405 Sec#141/231 |
| Net Assets | 78.98B KRW | KR#1,599/2,405 Sec#129/231 |
| Employees | 24 | KR#2,216/2,405 Sec#209/231 |
| Value | ||
| P/B | 24.02x | KR#2,392/2,405 Sec#227/231 |
| P/S | 689.84x | KR#2,395/2,405 Sec#226/231 |
| FCF Yield | -1.12% | KR—/2,405 Sec—/231 |
| Profitability | ||
| ROE | -27.54% | KR#2,147/2,405 Sec#169/231 |
| ROA | -22.30% | KR#2,251/2,405 Sec#183/231 |
| Op. Margin | -1367.89% | KR#2,367/2,405 Sec#217/231 |
| Revenue Growth | -62.42% | KR#2,296/2,405 Sec#208/231 |
| Financial Health | ||
| Debt Ratio | 23.50% | KR#450/2,405 Sec#53/231 |
| Total Debt | 2.54B KRW | KR#1,874/2,405 Sec#183/231 |
| FCF | -21.20B KRW | KR#1,896/2,405 Sec#182/231 |
| Cash | 32.88B KRW | KR#952/2,405 Sec#63/231 |
| Performance | ||
| 1Y Return | -40.71% | KR#1,753/2,405 Sec#145/231 |
| 1M Return | -4.07% | KR#617/2,405 Sec#62/231 |
| From 52W High | -64.62% | KR#1,867/2,405 Sec#156/231 |
| 1Y MDD | -68.17% | KR#1,877/2,405 Sec#159/231 |
| Trading | ||
| Volume | 332,039 shares | KR#237/2,405 Sec#14/231 |
| Trading Value | 13.58B KRW | KR#157/2,405 Sec#11/231 |
| Foreign Own. | 10.20% | KR#471/2,405 Sec#39/231 |
| Per Share | ||
| EPS | -473 KRW | KR—/2,405 Sec—/231 |
| BPS | 1,717 KRW | KR#2,138/2,405 Sec#180/231 |
Company Info
D&D Pharmatech, established in 2014 and listed on KOSDAQ in 2024, holds subsidiaries such as Neuraly Inc., Valted Seq Inc., and P4 Microbiome Inc. The company researches and develops new drugs for metabolic, neurodegenerative, and fibrotic diseases using technologies like GLP-1, with a diverse pipeline including oral obesity treatments. Leveraging new drug development capabilities through drug delivery technology, it advances its business via technology transfer and co-development with global partners. D&D Pharmatech is headquartered in Seongnam-si, Gyeonggi-do.